These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35222509)

  • 41. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges.
    D'Alessio A; Prete MG; Cammarota A; Personeni N; Rimassa L
    J Hepatocell Carcinoma; 2021; 8():177-191. PubMed ID: 33824862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort.
    von Felden J; Karkmann K; Ittrich H; Gil-Ibanez I; Fründt T; Krause J; Lohse AW; Wege H; Schulze K
    Visc Med; 2021 Mar; 37(2):87-93. PubMed ID: 33981749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Wu D; Jia B; Jia M; Zhao H; Zhao H; Zhou J
    Front Oncol; 2023; 13():1274754. PubMed ID: 38125936
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
    Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations.
    Debaillon Vesque A; Decraecker M; Blanc JF
    J Hepatocell Carcinoma; 2020; 7():91-99. PubMed ID: 32607316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCC and Molecular Targeting Therapies: Back to the Future.
    Rinaldi L; Vetrano E; Rinaldi B; Galiero R; Caturano A; Salvatore T; Sasso FC
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
    Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
    Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
    Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in pharmacotherapeutics for hepatocellular carcinoma.
    Cerrito L; Santopaolo F; Monti F; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Pharmacother; 2021 Jul; 22(10):1343-1354. PubMed ID: 33637024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.